Ryvu Therapeutics S.A. (WSE: RVU)

Ryvu Therapeutics Ratios and Metrics

Market cap in millions PLN. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Nov 20, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	1,008	1,329	1,139	1,120	903	719
Market Cap Growth	-20.25%	16.75%	1.70%	23.98%	25.66%	-16.36%
Enterprise Value	841	1,082	1,098	1,035	747	644
Last Close Price	43.60	57.50	49.25	61.00	49.20	45.00
PE Ratio	-	-	-	-	-	2.52
PS Ratio	11.06	19.75	16.64	31.62	24.44	21.31
PB Ratio	5.67	5.12	3.32	6.94	4.04	5.96
P/TBV Ratio	7.08	5.25	3.36	7.08	4.08	6.11
P/FCF Ratio	-	-	75.58	-	-	-
P/OCF Ratio	-	-	53.41	-	-	-
PEG Ratio	3.40	3.40	3.40	3.40	3.40	3.40
EV/Sales Ratio	9.23	16.08	16.05	29.21	20.22	19.10
EV/FCF Ratio	-6.39	-	72.90	-	-	-
Debt / Equity Ratio	0.46	0.04	0.04	0.08	0.03	0.08
Debt / FCF Ratio	-	-	0.84	-	-	-
Asset Turnover	0.22	0.15	0.19	0.14	0.15	0.18
Inventory Turnover	7.90	9.06	9.37	7.56	5.37	8.03
Quick Ratio	2.78	3.82	8.09	2.76	5.00	2.85
Current Ratio	3.03	3.99	8.21	2.88	5.10	2.94
Return on Equity (ROE)	-44.88%	-30.55%	-33.20%	-41.08%	-18.41%	-32.53%
Return on Assets (ROA)	-15.56%	-13.86%	-12.34%	-18.80%	-9.31%	-14.91%
Return on Capital (ROIC)	-23.58%	-19.46%	-16.37%	-24.31%	-12.37%	-19.64%
Earnings Yield	-10.36%	-6.93%	-7.36%	-7.06%	-3.51%	39.74%
FCF Yield	-13.06%	-7.01%	1.32%	-6.33%	-4.96%	-5.76%
Buyback Yield / Dilution	-6.52%	-24.75%	-	-9.48%	-4.98%	-2.89%
Total Shareholder Return	-6.52%	-24.75%	-	-9.48%	-4.98%	-2.89%

Source: S&P Capital IQ. Standard template. Financial Sources.